Leads Biolabs Gains Japan Orphan Drug Designation for Opamtistomig
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
Thousand Oaks, California, USA, September 8, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3 DeLLphi-305...
Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...
NANJING, China — August 25, 2026 Leads Biolabs announced that its proprietary Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has...
NANJING, China, August 20, 2026 Leads Biolabs announced that the full abstract for its Phase II study of LBL-024...
Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
IRVINE, Calif., July 31, 2026 enVVeno Medical Corporation reported its second quarter 2026 financial results, highlighting significant progress toward...
